Navigation Links
Pfizer Says Nigerian Court Lacks Jurisdiction to Hear Drug Case

US drug giant Pfizer Wednesday asked a Nigerian court to strike out a lawsuit against it by a state government over a failed 1996 drug test, saying the court lacked jurisdiction to hear the case.

Authorities in Kano, Nigeria's largest state, are seeking 2.75 billion dollars from Pfizer in compensation for the victims of the drug test which took place 11 years ago.

"This court has no jurisdiction to entertain this case ... I want this court to strike out this case", Pfizer's lawyer Anthony Idigbe told the court.

Kano government's lawyer Aliyu Umar asked for more time to enable him prepare his response to Pfizer's request.

Presiding judge Sanusi Ciroma Yusuf then adjourned the hearing to July 30.

The Kano government accuses Pfizer of administering a test antibiotic called Trovan without authorisation or parental consent among children at a field hospital during an epidemic in the city of meningitis, measles and cholera.

Of the 200 children affected, 11 died while many more -- reportedly 181 -- suffered from deafness, paralysis, brain damage and blindness, according to the allegations. Pfizer denies the charges.

The Nigerian federal government filed a similar lawsuit on June 4 in Abuja for almost seven billion dollars (5.2 billion euros) in damages against the US drug firm.

But the government's case suffered an early setback on June 26 when the court rejected a request to allow it to submit "additional facts", before presiding judge Babs Kwewumi adjourned the trial to July 20.

The US Food and Drug Administration (FDA) cleared Trovan for adult use in 1997 and the drug swiftly became established as one of the most prescribed antibiotics in the US market.


'"/>




Page: 1

Related medicine news :

1. Pfizer unveils anti-smoking drug
2. The Effectiveness Of The Breast Cancer Drug By Pfizer
3. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
4. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
5. Pfizer’s Eraxis Approved By The FD
6. Pfizer Launches Viagra For Lung Disease In UK
7. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
8. Pfizer Commences Its Advertising for Celebrex with All the Warnings
9. FDA Approves Pfizer’s Anti-smoking Dru
10. Pfizer vouches safety of long-term inhaled insulin.
11. NICE Setback Rules for Pfizers Inhaled Insulin
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles ... minutes later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised ... teen the hospital’s 30th heart transplant recipient. , “He was playing at home, when ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... One of ... changing of the securement tape is painful for her. "This is why the co-inventor ... patients’ heads," she said. , They then created a prototype of the patent-pending AV-AIR, ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
(Date:12/7/2016)... Studio City, CA (PRWEB) , ... December 07, 2016 , ... ... number during the holidays and winter seasons. One major study analyzing heart attacks ... January compared to August of a given year. We would all agree of course–no ...
(Date:12/7/2016)... ... ... “The Road To Restoration”: an informative and enlightening book for those who believe ... hands. “The Road To Restoration” is the creation of published author, Thomas Fitzhugh Sheets, ... that you could reach out for, and grab, on the old carousels. If ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 ... II trial in patients with unresectable malignant pleural ... survival (PFS). The data, presented at the 17 ... in Vienna , showed nintedanib ... to placebo plus pemetrexed/cisplatin, with a significantly improved ...
(Date:12/7/2016)... YORK , December 7, 2016 ... Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. ... DNAI ), and AveXis Inc. (NASDAQ: AVXS ... Sector Index fell roughly 37% to reach a level equal ... it is down by approximately 14% for the year, it ...
Breaking Medicine Technology: